OFFICIAL

Atty Docket No. 015389-002920US

PTO FAX NO.:

(703) 305-3014

FAX RECEIVED

ATTENTION:

Examiner Yvonne Eyler Group Art Unit 1642 JUN 1 1 1999

OFFICIAL COMMUNICATION

GROUP 1600

FOR THE PERSONAL ATTENTION OF

EXAMINER YVONNE EYLER

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following PRELIMINARY AMENDMENT and AMENDMENT TRANSMITTAL in re Application of Thomas Cech et al., Serial No. 08/846,017, filed April 25, 1997, for NOVEL TELOMERASE, are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 5

Dated: June 10, 1999

Susan L. Baka

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (650) 326-2422

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: (650) 326-2400

Fax: (650) 326-2422

PA 192487 v1

Amendment



Attorney Docket No. ___

15389-002920US

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 (650) 326-2400

In re application of: Thomas R. Chech et al.

Application No.: 08/846,017

Filed: April 25, 1997 Group Art Unit: 1642

For: NOVEL TELOMERASE

THE ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

I hereby certify that this correspondence is being sent by facsimile transmission to Examiner Yvonne Eyler at (703) 305-3014,

of Art Unit 1642 of the United States Patent and Trademark Office

June 10, 1999

TOWNSEND and TOWNSEND and CREW LLP

wan I Behre

Sir:

TOTAL

INDEP.

Transmitted herewith is an amendment in the above-identified application.

Enclosed is a petition to extend time to respond.

Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously [] submitted.

A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed. []

If any extension of time is needed, then this response should be considered a petition therefor.

The filing fee has been calculated as shown below:

[] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM

(Col. 1)

CLAIMS REMAINING

AFTER

AMENDMENT

*25

. 9

(Col. 2)

HIGHEST NO.

PREVIOUSLY

PAID FOR

** 23

(Col. 3)

PRESENT

EXTRA

2

1

RATE	ADDIT. FEE
x \$9.00 =	
x \$39.00 =	
+ \$130.00 =	
TOTAL ADDIT.	

SMALL ENTITY

OTHER THAN **SMALL ENTITY**

OR	RATE	ADDIT. FEE
	× \$18.00 =	\$36.00
	x \$78.00 =	\$78.00
	+ \$260.00 =	
OR	TOTAL	\$114.00

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, then write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

No fee is due.

MINUS

MINUS

Please charge Deposit Account No. 20-1430 as follows:

[X]Claims fee

Any additional fees associated with this paper or during the pendency of this application. [X]

extra copies of this sheet are enclosed.

TOWNSEND and TOWNSEND and CREW LLP

Randolph T. Apple Reg. No.: 36,429

Attorneys for Applicant

I hereby certify that this correspondence is being sent by facsimile transmission to Examiner Yvonne Byler at (703) 305-3014. of Art Unit 1642 of the United States Patent and Trademark Office

TOWNSEND and TOWNSEND and CREW LLP

Attorney Docket No.: 15389-002920

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEM

In re application of:

Thomas R. Cech et al.

Application No.: 08/846,017

Filed: April 25, 1997

For: NOVEL TELOMERASE

Examiner:

Yvonne Eyler

Art Unit:

1642

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please amend the claims as follows:

IN THE CLAIMS:

Please add the following new claims:

A pharmaceutical composition comprising an antisense oligonucleotide that hybridizes to a polynucleotide having the sequence of SEQ. I.D. No.: 100 and a carrier.

28. A method of detecting a condition or disease characterized by expression of a telomerase protein subunit comprising contacting a biological sample from a patient and a detectably labeled antibody capable of specifically binding the polypeptide of claim 26.--

07/02/1999 DWILLIA1 00000001 201430 08846017

01 FC:102 02 FC:103

18.00 CH |\$6.00 CH